STOCK TITAN
  1. Home
  2. Sec-filings
  3. RDHL
  4. [Form 3] RedHill Biopharma Ltd. Initial Statement of Beneficial Ownership

RedHill Biopharma (RDHL) CEO Ben-Asher details major share and option holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

RedHill Biopharma Ltd. director and Chief Executive Officer Dror Ben-Asher filed an initial ownership report showing substantial equity and option interests in the company. He directly holds 441,350,000 Ordinary Shares and 10,336 American Depositary Shares (ADSs)

The filing also discloses 44,135 unvested restricted share units (RSUs)750,000, 500,000, 900,000, and 1,100,000 Ordinary Shares at exercise prices of $5,000, $5,000, $4,870, and $7,080 per ADS, expiring between 2028 and 2031.

Positive

  • None.

Negative

  • None.
Insider Ben-Asher Dror
Role Chief Executive Officer
Type Security Shares Price Value
holding American Depositary Shares -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Ordinary Shares -- -- --
Holdings After Transaction: American Depositary Shares — 103,360,000 shares (Direct); Stock Option (Right to Buy) — 750,000 shares (Direct); Ordinary Shares — 441,350,000 shares (Direct)
Footnotes (1)
  1. Represents 44,135 unvested restricted share units ("RSUs"), each with respect to one American Depositary Share ("ADS"), which represents 10,000 ordinary shares, par value NIS 0.01 per share ("Ordinary Shares"), of RedHill Biopharma Inc. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. Represents 10,336 ADSs, which are convertible at any time, at the holder's election and have no expiration date. Represents stock option to purchase 750,000 Ordinary Shares (equivalent to 75 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on May 6, 2029. Represents stock option to purchase 500,000 Ordinary Shares (equivalent to 50 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on March 21, 2028. Represents stock option to purchase 900,000 Ordinary Shares (equivalent to 90 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $4,870 per ADS and the option expires on March 25, 2030. Represents stock option to purchase 1,100,000 Ordinary Shares (equivalent to 110 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $7,080 per ADS and the option expires on April 28, 2031.
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Ben-Asher Dror
(Last)(First)(Middle)
21 HA'ARBA'A STREET
(Street)
TEL AVIV6473921
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
RedHill Biopharma Ltd. [ RDHL ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares441,350,000(1)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
American Depositary Shares (2) (2)Ordinary Shares103,360,000(2)D
Stock Option (Right to Buy) (3) (3)Ordinary Shares750,000(3)D
Stock Option (Right to Buy) (4) (4)Ordinary Shares500,000(4)D
Stock Option (Right to Buy) (5) (5)Ordinary Shares900,000(5)D
Stock Option (Right to Buy) (6) (6)Ordinary Shares1,100,000(6)D
Explanation of Responses:
1. Represents 44,135 unvested restricted share units ("RSUs"), each with respect to one American Depositary Share ("ADS"), which represents 10,000 ordinary shares, par value NIS 0.01 per share ("Ordinary Shares"), of RedHill Biopharma Inc. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares.
2. Represents 10,336 ADSs, which are convertible at any time, at the holder's election and have no expiration date.
3. Represents stock option to purchase 750,000 Ordinary Shares (equivalent to 75 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on May 6, 2029.
4. Represents stock option to purchase 500,000 Ordinary Shares (equivalent to 50 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on March 21, 2028.
5. Represents stock option to purchase 900,000 Ordinary Shares (equivalent to 90 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $4,870 per ADS and the option expires on March 25, 2030.
6. Represents stock option to purchase 1,100,000 Ordinary Shares (equivalent to 110 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $7,080 per ADS and the option expires on April 28, 2031.
/s/ Dror Ben-Asher03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does Dror Ben-Asher’s Form 3 filing show for RedHill Biopharma (RDHL)?

The Form 3 shows Dror Ben-Asher, CEO of RedHill Biopharma, reporting significant direct ownership of Ordinary Shares, ADSs, RSUs, and stock options. It establishes his initial beneficial holdings as a company insider without indicating any recent share purchases or sales.

How many RedHill Biopharma Ordinary Shares does the CEO report owning on Form 3?

The CEO reports direct ownership of 441,350,000 Ordinary Shares. This base equity position is supplemented by ADSs, unvested RSUs, and vested stock options, giving him multiple layers of exposure to RedHill Biopharma’s equity beyond the core Ordinary Share holding.

What American Depositary Shares (ADSs) and RSUs are disclosed in the RDHL Form 3?

The filing discloses 10,336 ADSs that are convertible at any time with no expiration date. It also lists 44,135 unvested RSUs, each linked to one ADS representing 10,000 Ordinary Shares, subject to time-based vesting and settled in Ordinary Shares when vested.

What stock options does RedHill Biopharma’s CEO hold according to the Form 3?

The CEO holds fully vested stock options to purchase 750,000, 500,000, 900,000, and 1,100,000 Ordinary Shares. Exercise prices are $5,000, $5,000, $4,870, and $7,080 per ADS, with expirations between 2028 and 2031.

Does the RedHill Biopharma (RDHL) Form 3 indicate any insider buying or selling?

No, the Form 3 reflects initial beneficial ownership rather than new trades. The transaction summary shows holdings and unknown transaction codes, with no recorded buy or sell entries, so it serves as a baseline disclosure of the CEO’s existing equity interests.

How are RedHill Biopharma RSUs described in the CEO’s Form 3 filing?

The filing describes 44,135 RSUs tied to one ADS each, with each ADS representing 10,000 Ordinary Shares. These RSUs vest over time based on service conditions and are settled in Ordinary Shares when vested, adding a deferred equity component to the CEO’s compensation.